Innovation Associate for highly specific Tumour Associated Carbohydrate Antigens

CellmAbs is a recent but fast growing biopharmaceutical spinoff dedicated to the development of immuno-oncology agents that target only cancer cells, promoting the activation of the immune system and inhibiting growth of cancer in both early and late stages.In spite of many advances in diagnostic and treatment development, many cancers still have no targeted therapy or have limited or toxic treatment options.

Early detection is crucial to optimize treatment and substantially reduce incidence and mortality.

In spite of the advent of new and improved genomic and proteomic technologies, it has not been possible to identify cancer-specific therapeutic targets or molecules that are able to reliably and accurately predict outcomes during cancer management and treatment.

Cancers such as colorectal cancer (CRC) have very poor standard of care and thus own an unmet need for reliable and specific targets.

The discovery of tumour associate carbohydrate antigens (TACA) is very promising but is still very insipient due to lack of experts, knowledge and technology on the field.InnoTACA will address several unmet needs by presenting the grounds for hiring an Innovation Associate with relevant expertise and experience on groundbreaking technology to innovate TACA discovery to apply in cancer theranostic, combining high-quality transferable-skill training with excellent scientific training in glycomics.

InnoTACA addresses the CellmAbs need of identifying highly specific TACAs, which would serve as a lead for the development of safer and more cost-effective immunotherapies, even for advanced unresectable CRC.

The InnoTACA Associate and such immunotherapies will provide CellmAbs with improved products to capitalize and compete with current healthcare business and it will allow CellmAbs to connect with other high-tech SMEs focused in pharmaceutical and medical development, and partners with strong translational clinical and research backgrounds.